USPTO serial 79139380
XL-PROTEIN
Reviewed by CopyMark Law Group
Reg. 4634784Status 404
- Filing date
- Status date
- Registration date
- Nov 11, 2014
- Examiner
- MORENO, PAUL A
- Law office
- POST REGISTRATION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with XL-PROTEIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anthony G. Craig
Anthony G. Craig Sci-Law Strategies, P.C.P.O. Box 1729Solana Beach, CA 92075UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemical and biochemical preparations for use in research and laboratories, except for medical and veterinary use, as well as for industrial and scientific use; ] unprocessed artificial resins, unprocessed plastics | SECTION 71 - CANCELLED | — |
| 005 | [ Pharmaceutical and veterinary preparations, preparations for human medical purposes for use in treating growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; ] sanitary preparations for medical purposes; [ dietetic substances adapted for medical use, namely, nutritional supplements containing proteins, peptides, food for babies; ] preparations for destroying vermin; fungicides, herbicides [ ; pharmaceutical and diagnostic preparations for medical, dental and forensic purposes and for purposes of forensic medicine and laboratory medicine, namely, pharmaceutical and diagnostic preparations for diagnosis, prevention, treatment or cure of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; testing reagents in kit form for medical, dental and forensic purposes and for purposes of forensic medicine and laboratory medicine, namely, medical and forensic diagnostic reagents and assays for testing of body tissues and body fluids; chemical and biotechnological preparations for medical and diagnostic purposes, namely, reagents and solvents for sample preparation, modification and manipulation of cells and for performing of marking, separation, isolation, purification, amplification and/or analytical methods for biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances for diagnostic purposes included in this class; medicaments for preventive, curative and palliative purposes for preventing, treating or curing of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; medical biomarkers, in particular for preventative, diagnostic, prognostic or predictive purposes, namely, polypeptide sequences; medical preparations, namely, kits for laboratory medicine in particular for preventive, diagnostic, prognostic or predictive purposes, namely, diagnostic kits consisting primarily of proteins, buffers, and reagents for use in detecting growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; biomolecules (targets) for medical purposes, namely, proteins, peptides and small molecule drugs with conjugated polypeptide sequences for binding of active substances; medical preparations for analytical purposes, namely, reagents for detecting growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; preparations for health care, namely, for diagnosis, prevention, treatment, or cure of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases ] | SECTION 71 - CANCELLED | — |
| 042 | [ Scientific and technological services and research, namely, scientific research, analysis, testing, in the field of chemistry, genetics, biology, biotechnology and biochemistry; technical services, namely, computer diagnostic services in the field of DNA, RNA and protein expression, detection and analysis and respective design services, in particular in the field of chemistry, genetics, biology, biotechnology and biochemistry; industrial analysis and research services in the field of medical, dental, forensic and scientific research; ] design and development of computer hardware [ and software; services of a chemical and biochemical laboratory; scientific research including conducting of scientific examinations and preparation of scientific opinions; quality checking, namely, quality evaluation services for the medical and pharmaceutical industry; design and development of programs for data processing; consultancy for scientific, laboratory and research purposes in the field of chemistry, genetics, biology, biotechnology and biochemistry; scientific services of a technical measuring and test laboratory; technological consulting services pertaining to scientific and industrial scientific research in the fields of generation, technical processing and technical analysis of biomaterials and medically relevant data ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by XL-protein GmbH
- Other trademarks owned by XL-protein GmbH
- Other trademarks owned by XL-protein GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named XL-PROTEIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 20, 2023 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Nov 20, 2023 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jul 17, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| May 20, 2022 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 20, 2022 | INPC | INVALIDATION PROCESSED | — |
| Jan 28, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 28, 2021 | C71T | CANCELLED SECTION 71 | — |
| Sep 23, 2020 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Sep 23, 2020 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 14, 2020 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Jan 13, 2020 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jan 13, 2020 | PLGL | ASSIGNED TO PARALEGAL | — |
| Nov 11, 2019 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 9, 2019 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jul 13, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 24, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 2, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 2, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 11, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 11, 2014 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 26, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 26, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 22, 2014 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 6, 2014 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 6, 2014 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 6, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 18, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 18, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 26, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 26, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 16, 2014 | ALIE | ASSIGNED TO LIE | — |
| Jun 4, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 31, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 13, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 10, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 10, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 10, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 9, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 9, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 6, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |